Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. - Wikidata - wikimedia - TriplyDB

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

http://www.wikidata.org/entity/Q42663487

about

Phosphodiesterase 4-targeted treatments for autoimmune diseases New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast Emerging drugs for uveitis Jakpot! New small molecules in autoimmune and inflammatory diseases Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms Etiology and management of pyoderma gangrenosum: a comprehensive review.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Apremilast.Ciclamilast ameliorates adjuvant-induced arthritis in a rat model Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study.Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.Small molecular therapies for rheumatoid arthritis: where do we stand?Altered bone biology in psoriatic arthritis.Apremilast as a treatment for psoriasis.The role of biologic agents in the management of non-infectious uveitis.Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.Novel small molecule therapeutics in rheumatoid arthritis.Emerging therapies for rheumatoid arthritis.Emerging immunotherapies for rheumatoid arthritis.Apremilast: first global approval.Novel treatments with small molecules in psoriatic arthritis.Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Emerging drugs for psoriatic arthritis.Psoriatic arthritis and psoriasis: differential diagnosis.Apremilast in the treatment of psoriatic arthritis: a perspective review.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Apremilast: A Review in Psoriasis and Psoriatic Arthritis.The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1 [Guidelines for vaccination of immunocompromised individuals].Activity-Guided Isolation of Bioactive Constituents with Antinociceptive Activity from Muntingia calabura L. Leaves Using the Formalin Test.Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate.Cγ1 Deficiency Exacerbates Collagen-Induced Arthritis.Discover natural compounds as potential phosphodiesterase-4B inhibitors via computational approaches.Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats.

P2860

Q21245284-09BD3DF1-218B-4AD2-A1E1-D4A792637E21 Q22305855-29D0F8E7-8AA3-4271-A505-3E8B457856B4 Q24630848-729AAAF5-4E0F-4FDC-A45E-022E52B338F2 Q27001957-171F3E75-A546-4282-AF13-6999101D4068 Q27681871-408367CF-3FA3-492B-A564-983C62DA80E2 Q28530398-CA6CE2A6-36FD-4C01-A5F0-9EE9044836DB Q34030811-8092C732-A4BE-41C3-B9BA-A7500EA6CB5C Q34253548-CFC22DB9-F455-4370-91A1-9F06DFF14F82 Q34612877-2FAAA0AC-EFA1-415E-90F3-AB4471DCC5A9 Q35591323-B0A911F1-ED74-44C8-B05E-A6CF6990EEAE Q36061710-1B310270-3FBE-43D1-8E9B-759B6A1E1213 Q36923514-09204F25-F27B-4CC9-B76F-B2C94E71C01F Q36942993-4300896A-568B-4EE6-9181-D82E4BAD446B Q37046760-585636F8-4F1C-463F-B748-5AFB38CF3AEA Q37104915-F4F98108-0720-40F1-8CF2-5EE35F33035F Q37462071-B7FEAB5E-F6AE-4488-9E25-783D82D725FF Q37954363-BA201632-15C7-44B7-993C-142BD7C2FEF0 Q38010645-E5B089DD-F69C-499A-95D3-033A5B411597 Q38019980-2D27D59F-8BE1-488E-8930-4EDA53403965 Q38025152-228F988C-87F5-46E2-94DC-1248EDDFD27D Q38032568-8EAD3F35-1F6F-402E-B0F8-36678E2E7033 Q38072417-4113C064-7A22-42A3-A023-1E2DA8D78959 Q38110963-420C0E3D-CF07-4D25-B0F3-95E81FACBDE0 Q38188862-B8C5FE51-A58B-4DE0-ACE1-DD25897B059D Q38209439-40B5822C-D185-468A-981A-0D62157B534A Q38229893-DB6A5122-EE14-48B0-A426-3D018408CB40 Q38416536-CC521F4B-1299-4171-A9D7-69499BC8DC97 Q38697262-BE22C809-9136-4B40-A187-A29D0437421A Q38710642-3134F538-1EE3-4522-9B18-CCFCC5218C98 Q38828427-E2ADE614-2544-4553-AD07-497CA266D824 Q38932094-F5A69E9C-EE9D-4CCE-9228-7FDD1C111038 Q38984735-5BF3A8D1-056C-46AA-BBF4-AEB61C5303D4 Q39141679-47F12C0D-0B0A-45FF-98BE-0A28B7A468FD Q40204659-8ED5B391-4241-474F-851A-3CA80AD031D5 Q40600058-3E03BBAD-F161-406D-9C99-E1902BE8C3D4 Q42835819-4FB5D162-B8F0-4F4D-A424-D97689BFB833 Q46120241-1619E454-71EA-48D0-95F2-F6D002280A39 Q48065360-085C9303-A92D-4C94-9A0E-E04A94D805AD Q51614228-30C038DB-2705-4046-A378-B51539420029 Q51772071-C53C610A-F676-47E5-8E52-ECBF59C80E0D

P2860

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

http://www.wikidata.org/entity/Q42663487

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@en

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@nl

type

label

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@en

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@nl

prefLabel

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@en

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@nl

P1433

Q42663487-AAB15A3A-914F-4415-9F08-4E8EC5EC00ED

P1476

Q42663487-D408F5F1-78F2-46FF-A210-3388849F191F

P2093

Q42663487-036725EE-71B0-4760-99E8-FCF151113E27

Q42663487-097C4040-A01D-4821-8513-A2CD3535607A

Q42663487-34892FD4-735C-4741-92FD-F037B2B17C44

Q42663487-4D356D58-D50B-4D70-81D6-38D60CED21E9

Q42663487-546A055D-7FC2-4693-9B25-2912F0F72DEC

Q42663487-C4BB90ED-0D02-45E5-867B-92F427D5943B

Q42663487-E31846DB-875A-4DFF-9ECB-105E2026298C

Q42663487-EC3C1F12-A4AE-4A4D-AAC3-DA468288CFB5

P2860

Q42663487-02C5F9F4-F40D-4C03-B27A-E4AEB447916C

Q42663487-05F0B576-C8D4-4620-A3E6-7C9190E76966

Q42663487-0A8A2AD4-E141-42FD-9DAD-6686738B088E

Q42663487-1326E92E-26D8-4C23-98BC-EA92AEE49C69

Q42663487-1D5ECCCD-F157-4C98-884D-434DFAE21EC6

Q42663487-1E174D9A-ED16-4D16-8371-A2427B17D5F0

Q42663487-24614ECD-4691-4947-A430-4EB0E73BB849

Q42663487-28F61E02-EA3C-48BB-9052-3DF9FB89CCDB

Q42663487-2DF118C7-0A49-40E8-918A-DA4D1F984AB2

Q42663487-33423926-2925-4F8E-A84D-23127DDE6820

P2888

Q42663487-260BB271-814C-4312-A55D-F2D5DC4BE200

P304

Q42663487-D1E721C9-3E45-431F-92D0-0340EB39F573

P31

Q42663487-5A92F2E7-A9D0-4558-8B69-329C3D55EF81

P356

Q42663487-DA1F02B2-EBA6-4CB3-90B7-F7B08F0D1B00

P433

Q42663487-3AD8F796-A3F5-4BB1-B72D-00AD3E353018

P478

Q42663487-D643CD53-7DF9-429D-8728-5393B0BE5DC8

P50

Q42663487-A7630585-2B35-46C2-AB4D-AEC33554C7A6

P577

Q42663487-310FBECE-EA58-4F74-86CC-71E030C16211

P5875

Q42663487-FBE055C9-5358-41A0-8946-A595E5A52E04

P6179

Q42663487-E3A55BD0-8E17-4569-961B-847D3EA61898

P698

Q42663487-9A64CC69-8DB3-4317-B4AE-DF1ACFD3884B

P921

Q42663487-a512807d-79d8-40a5-abc8-f083c992d652

P932

Q42663487-BC66C43B-CB80-4135-BDB8-AD869BDB6900

P356

P1433

Arthritis Research and Therapy

P1476

Apremilast, a novel PDE4 inhib ...... orates experimental arthritis.

@en

P2093

Andrew C Palfreeman

http://www.w3.org/2001/XMLSchema#string

Dany P Perocheau

http://www.w3.org/2001/XMLSchema#string

Fionula M Brennan

http://www.w3.org/2001/XMLSchema#string

Julia J Inglis

http://www.w3.org/2001/XMLSchema#string

Marc Feldmann

http://www.w3.org/2001/XMLSchema#string

Melanie Andrews

http://www.w3.org/2001/XMLSchema#string

Peter Schafer

http://www.w3.org/2001/XMLSchema#string

Richard O Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast

PDE4 inhibitors: current status

Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

Keynote review: phosphodiesterase-4 as a therapeutic target

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Molecular diversity of cyclic AMP signalling.

P2888

P304

R107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR3041

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44651176

http://www.w3.org/2001/XMLSchema#string

P6179

1020108588

http://www.w3.org/2001/XMLSchema#string

P698

20525198

http://www.w3.org/2001/XMLSchema#string

P921

P932

2911898

http://www.w3.org/2001/XMLSchema#string